Evidence map›Paper›PMID 37839090›Full record

ArticleEpigenetics2023

Utility of

Atsushi Watanabe, Kunio Miyake, Yuriko Yamada, Ei-Ichiro Sunamura, Takuya Yotani, Keiko Kagami, Shin Kasai, Minori Tamai, Daisuke Harama, Koshi Akahane and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epigenetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Atsushi WatanabeDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0002-4181-8111
Kunio MiyakeDepartment of Epidemiology and Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Yuriko YamadaTsukuba Research Institute, Research and Development, Sekisui Medical Co, Ltd, Ibaraki, Japan.
Ei-Ichiro SunamuraTsukuba Research Institute, Research and Development, Sekisui Medical Co, Ltd, Ibaraki, Japan.
Takuya YotaniInstrument System Development Center, Research and Development, Sekisui Medical Co, Ltd, Ibaraki, Japan.
Keiko KagamiDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Shin KasaiDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Minori TamaiDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0001-6905-4582
Daisuke HaramaDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0002-2967-6739
Koshi AkahaneDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0001-8591-1281
Kumiko GoiDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Kimiyoshi SakaguchiDepartment of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.ORCID 0000-0002-3665-401X
Hiroaki GotoHematology/Oncology, Kanagawa Children's Medical Center, Kanagawa, Japan.
Shinichiro KitaharaR&D Management Department, Research and Development, Sekisui Medical Co, Ltd, Tokyo, Japan.
Takeshi InukaiDepartment of Pediatrics Environmental Medicine, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID 0000-0002-4783-2184
University of Yamanashi · JPSekisui Medical (Japan) · JPHamamatsu University School of Medicine · JPKanagawa Children's Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asparaginase is an important agent for the treatment of acute lymphoblastic leukaemia (ALL), but it is occasionally associated with severe adverse events. Thus, for safer and more efficacious therapy, a clinical biomarker predicting asparaginase sensitivity is highly anticipated. Asparaginase depletes serum asparagine by deaminating asparagine into aspartic acid, and ALL cells are thought to be sensitive to asparaginase due to reduced asparagine synthetase (ASNS) activity. We have recently shown that allele-specific methylation of the

Indexed as

Aspartate-Ammonia LigasePrecursor Cell Lymphoblastic Leukemia-LymphomaAsparaginaseAsparagineCell Line, TumorChromatography, High Pressure LiquidDNA MethylationHumansPharmacogeneticsSulfitesAsparaginaseAsparagineAspartate-Ammonia Ligasehydrogen sulfiteSulfitesacute lymphoblastic leukaemiaasparagine synthetaseDNA methylationhigh-performance liquid chromatographyprecision medicine

Identifiers

PMID37839090
PMCPMC10578186
OpenAlexW4387652922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.